Earnings Releases

Enveric Biosciences, Inc. reported fourth quarter and fiscal year ended December 31, 2023 results: net income $3.44 million for the fourth quarter ended December 31, 2023, EPS $1.46.

“Net loss attributable to stockholders was $3.44 million for the fourth quarter ended December 31, 2023, including $1.48 million in net non-cash expense, with a basic and diluted loss per share of $1.46, as compared to a net loss of $8.80 million, including $4.48 million in net non-cash expense, with a basic and diluted loss per share of $4.89 for the quarter ended December 31, 2022.”

DELCATH SYSTEMS, INC. reported fourth quarter and full year ended December 31, 2023 results: revenue approximately $0.5 million and $2.1 million, respectively. Guidance raised.

“to year-end, on March 19, 2024, the company closed a $7.0 million private placement financing. Total revenue for the quarter and year-ended December 31, 2023, was approximately $0.5 million and $2.1 million, respectively, compared to $0.6 million and $2.7 million for the same periods in the prior year, respectively, from our sales of CHEMOSAT in Europe. Research and”

PROGRESS SOFTWARE CORP /MA reported financial results for the fiscal first quarter ended February 29, 2024.

“On March 26, 2024, Progress Software Corporation ("Progress") issued a press release announcing its financial results for the fiscal first quarter ended February 29, 2024.”

INTRUSION INC reported the fourth quarter ended December 31, 2023 results: revenue $1.4 million, net income $(2.8) million, or $(0.09) per share, EPS $(0.09) per share.

“and equity standard requirements. · Continuing resolution negatively impacts consulting revenues. Fourth Quarter Financial Results Revenue for the fourth quarter of 2023 was $1.4 million, a decrease of 7% sequentially and 5% compared to the previous year. The decline in revenue during the fourth quarter of 2024 was driven by a decrease in consulting revenue that”

INTRUSION INC reported the year ended December 31, 2023 results: revenue $5.6 million, net income $13.9 million, or $(0.57) per share, EPS $(0.57) per share.

“to a loss of $(5.2) million, or $(0.25) per share for the fourth quarter of 2022. Full Year 2023 Financial Results Revenue for the full year ended December 31, 2023, was $5.6 million, a decrease of $1.9 million compared to 2022. The gross profit margin was 78% for the full year ended December 31, 2023, compared to 55% in 2022. Operating expenses for the full”

MOVADO GROUP INC reported financial results for the fourth quarter and fiscal year 2024 results for the periods ended January 31, 2024.

“On March 26, 2024, Movado Group, Inc. (the “Company”) issued a press release announcing results for the fourth quarter and fiscal year 2024 results for the periods ended January 31, 2024.”

MCCORMICK & CO INC reported three months ended February 29, 2024 results: EPS $0.62.

“Adjusted earnings per share was $0.63 compared to $0.59 in the year-ago period, reflecting a 7% increase year-over-year.”

MCCORMICK & CO INC updated its first quarter for fiscal year 2024 ended February 29, 2024 guidance (reaffirmed).

“McCormick & Company, Incorporated (NYSE:MKC), a global leader in flavor, today reported financial results for the first quarter ended February 29, 2024 and reaffirmed fiscal 2024 outlook.”

Kyverna Therapeutics, Inc. reported the full year ended December 31, 2023 results: net income net loss of $60.4 million, or a net loss per common share of $89.61, EPS net loss per common share of $89.61.

“For the year ended December 31, 2023, the company reported a net loss of $60.4 million, or a net loss per common share of $89.61, compared to a net loss of $28.9 million, or a net loss per common share of $63.43, for the same period in 2022.”

NCR Atleos Corp reported the three months ended December 31, 2023 results: revenue $1.098 billion, net income Net loss attributable to Atleos of $165 million, EPS GAAP basis diluted loss per share attributable to Atleos of $2.34 and Non-GAAP diluted earnings per share of $0.64. Guidance reaffirmed.

“separation transaction from NCR Corporation on October 16 th • More than 20,000 ATM as a Service active units at year-end • Solid fourth quarter results, including: – Revenue of $1.1 billion, up 3% year-over-year; recurring revenue of $777 million, up 10% year-over-year – Net loss attributable to Atleos of $165 million on a GAAP basis; GAAP basis diluted loss per”

Mural Oncology plc reported the fourth quarter ended December 31, 2023 results: net income Net loss was $59.5 million for the fourth quarter of 2023.. Guidance reaffirmed.

“Net loss was $59.5 million for the fourth quarter of 2023.”

Worthington Steel, Inc. reported the three months ended February 29, 2024 (the third quarter of fiscal 2024) and the nine months ended February 29, 2024 results: revenue $805.8 million, net income $49.0 million, EPS $0.98 per diluted share.

“Worthington Steel, Inc. (NYSE: WS) today reported financial results for the fiscal 2024 third quarter ended February 29, 2024. The Company reported net sales of $805.8 million and net earnings attributable to controlling interest of $49.0 million, or $0.98 per diluted share, for its fiscal 2024 third quarter.”

ProSomnus, Inc. reported financial results for three- and twelve-months ended December 31, 2023.

“On March 26, 2024, ProSomnus, Inc. (“ProSomnus” or the “Company”) issued a press release announcing our financial results for the three- and twelve-months ended December 31, 2023.”

Third Harmonic Bio, Inc. reported fourth quarter and full year ended December 31, 2023 results: net income Net loss for the three months ended December 31, 2023 decreased to $6.8 million from a net loss of $11.5 million for the.

“Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results”

nCino, Inc. reported fourth quarter and fiscal year ended January 31, 2024 results: revenue $123.7M, net income $1.2 million, EPS $0.01 per diluted share. Guidance initiated.

“unless expressly incorporated by reference in such filing. --- EX-99.1 (EX-99.1) --- nCino Reports Fourth Quarter and Fiscal Year 2024 Financial Results Q4 Total Revenues of $123.7M, up 13% year-over-year Fiscal Year 2024 Total Revenues of $476.5M, up 17% year-over-year Q4 Subscription Revenues of $107.5M, up 16% year-over-year Fiscal Year 2024 Subscription”

Direct Digital Holdings, Inc. updated its fiscal year ended December 31, 2023 guidance (raised).

“On March 26, 2024, Direct Digital Holdings, Inc. issued a press release announcing its financial results for the fiscal year ended December 31, 2023.”

Hour Loop, Inc reported full year 2024 results: revenue $145 million to $172 million, net income $0.5 million to $2 million. Guidance initiated.

“For the full year 2024, Hour Loop is providing guidance for net revenue to be in the range of $145 million to $172 million, representing 10% to 30% year-over-year growth. The Company expects 2024 net income to be in the range of $0.5 million to $2 million.”

Hour Loop, Inc reported the year ended December 31, 2023 results: revenue $132.1 million, net income ($2.4 million), EPS ($0.07) per diluted share. Guidance initiated.

“leading online retailer, announces its financial and operational results for the year ended December 31, 2023. Financial Highlights for 2023: ● Net revenues increased 37.7% to $132.1 million, compared to $95.9 million in 2022; ● Net loss totaled $2.4 million, compared to net loss $1.5 million in 2022; and ● Cash used for operating activities was $2.1 million and”

Volato Group, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.

“On March 26, 2024, Volato Group, Inc. (the "Company") issued a press release announcing its financial results for the three months and fiscal year ended December 31, 2023. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.”

Perfect Moment Ltd. reported three and nine months ended December 31, 2023 results: net income Net income totaled $1.2 million, or $0.23 per basic share and $0.08 per diluted share.

“On March 25, 2024, Perfect Moment Ltd. issued a press release reporting its financial results for the three and nine months ended December 31, 2023.”

Marpai, Inc. reported the year ended December 31, 2023 results: revenue $37.2 million, net income Net loss was $28.8 million, EPS ($4.14).

“Net revenues were $37.2 million for the year ended December 31, 2023, an improvement of $12.8 million, or 52.6% higher year over year compared to the year ended December 31, 2022.”

Marpai, Inc. reported the three months ended December 31, 2023 results: revenue $8.7 million, net income Net loss was $5.0 million, EPS ($0.65).

“Net revenues were $8.7 million for the three months ended December 31, 2023, an improvement of $1.1 million, or 14% higher year over year, for the three months ended December 31, 2022.”

Forge Global Holdings, Inc. reported year ended December 31, 2023 results: revenue $69.4 million, net income $91.5 million.

“Financial Highlights for the Full Year 2023 • Revenue : Total revenue less transaction-based expenses was $69.4 million compared to $68.9 million for the year ended December 31, 2022. • Operating Income: Total operating loss was $91.4 million compared to $135.0 million for the year ended December 31, 2022. • Net Loss: Net loss of $91.5 million compared to $111.9 million for the year ended December 31, 2022.”

Forge Global Holdings, Inc. reported quarter ended December 31, 2023 results: revenue $18.9 million, net income $26.2 million.

“Financial Highlights for the Fourth Quarter of 2023* Revenue : Total revenue less transaction-based expenses increased from $18.4 million in the quarter ended September 30, 2023 to $18.9 million in the quarter ended December 31, 2023. Operating Income: Total operating loss went from $21.5 million in the quarter ended September 30, 2023 to $24.4 million in the quarter ended December 31, 2023. Net Loss: Net loss went from $19.0 million in the quarter ended September 30, 2023 to $26.2 million in the quarter ended December 31, 2023.”

Vigil Neuroscience, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.

“Vigil Neuroscience, Inc . (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the fourth quarter and full year ended December 31, 2023”

BioAtla, Inc. reported financial results for fourth quarter and full year ended December 31, 2023.

“BioAtla, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023”

Concentrix Corp reported the fiscal first quarter ended February 29, 2024 results: revenue $ 2,402.7, net income $ 52.1, EPS $ 0.76. Guidance reaffirmed.

“technology, today announced financial results for the fiscal first quarter ended February 29, 2024. Three Months Ended February 29, 2024 February 28, 2023 Change Revenue ($M) $ 2,402.7 $ 1,636.4 46.8 % Operating income ($M) $ 148.4 $ 156.0 (4.9) % Non-GAAP operating income ($M) (1) $ 319.1 $ 217.6 46.6 % Operating margin 6.2 % 9.5 % -330 bps Non-GAAP operating”

Gain Therapeutics, Inc. reported the year ended December 31, 2023 results: net income $22.3 million, EPS $1.71.

“Net loss for the year ended December 31, 2023 was $22.3 million, compared to a net loss of $17.6 million for the year ended December 31, 2022.”

AEye, Inc. reported the fourth quarter and year ended December 31, 2023 results: revenue $0.1 million, net income $(27.8) million, or $(4.44) per share, EPS $(4.44) per share.

“the company effected a 1-for-30 reverse stock split and all the financial information disclosed has been adjusted to account for the revised share count numbers. ● Revenue of $0.1 million in the fourth quarter of 2023. ● GAAP net loss was $(27.8) million, or $(4.44) per share, based on 6.3 million weighted average common shares outstanding. ● Non-GAAP net loss was”

Ouster, Inc. reported the three and twelve months ended December 31, 2023 results: revenue Over $83 million in revenue, net income Net loss of $39 million. Guidance initiated.

“Ouster Announces Record Revenue for Fourth Quarter and Full Year 2023 Record revenue of $83 million for the full year 2023 Expects $25 to $26 million of revenue for the first quarter of 2024”

BODY & MIND INC. reported financial results for the second quarter of fiscal year 2024 ended January 31, 2024.

“Body and Mind Inc. (the “Company” or “BaM”) issued a news release announcing its financial results for the second quarter of fiscal year 2024 ended January 31, 2024.”

Virpax Pharmaceuticals, Inc. reported financial results for twelve months ended December 31, 2023.

“On March 26, 2024, Virpax Pharmaceuticals, Inc., a Delaware corporation (the “Registrant”), issued a press release that included financial information for its fiscal year ended December 31, 2023.”

Korro Bio, Inc. reported the year ended December 31, 2023 results: net income $81.2 million.

“Korro’s net loss was $81.2 million for the year ended December 31, 2023, as compared to $58.0 million for the year ended December 31, 2022.”

Datavault AI Inc. reported the full year ended December 31, 2023 results: revenue in the range of $1.9 million to $2.1 million, net income in the range of $17.7 million to $19.7 million. Guidance initiated.

“Total revenue for the full year 2023 is expected to be in the range of $1.9 million to $2.1 million. The net loss for the full year 2023 is expected to be in the range of $17.7 million to $19.7 million as compared to a net loss of $16.2 million for the year 2022. The company has signed 3 licensing agreements with TV/PTV companies and expects that an additional 3 license agreements will be signed by the end of Q2'24.”

Flutter Entertainment plc updated its fiscal year ending December 31, 2024 guidance (initiated).

“Guidance for fiscal year ending 31 December 2024 introduced, with Group revenue growth of 17.5% at the midpoint.”

Flutter Entertainment plc reported fiscal year ended December 31, 2023 results: revenue 11,790, net income (1,211), EPS $(6.89).

“Key financial highlights: In $ millions except percentages and AMPs Fiscal year ended December, 31 2023 2022 YOY Average monthly players (‘000s) 1 12,325 10,245 +20.3 % Revenue 11,790 9,463 +24.6 % Net loss (1,211 ) (370 ) (227.3 %) Further Adjusted EBITDA 2 1,874 1,289 +45.4 % Further Adjusted EBITDA Margin 2 15.9 % 13.6 % +230bps Net loss per share $ (6.89 ) $ (2.44 ) (182.4 %) Adjusted Earnings per share ($) 2 $ 3.51 $ 2.79 +25.8 %”

OXBRIDGE RE HOLDINGS Ltd reported the quarter and year ended December 31, 2023 results: net income net loss of $9.9 million, EPS ($1.69) per basic and diluted loss per share.

“the Company incurred a net loss of $9.9 million or ($1.69) per basic and diluted loss per share compared to net loss of $1.8 million or ($0.31) per basic and diluted earnings per share in the prior year.”

Acumen Pharmaceuticals, Inc. reported the year ended December 31, 2023 results: net income $52.4 million.

“Net loss for the year ended December 31, 2023 was $52.4 million”

Keenova Therapeutics plc updated its the fourth quarter and fiscal year ended December 29, 2023 guidance (raised).

“On March 26, 2024, Mallinckrodt plc provided its financial results for the three months and year ended December 29, 2023 as set forth in the attached Exhibit 99.1.”

Annexon, Inc. reported financial results for fourth quarter and the year ended December 31, 2023.

“On March 26, 2024, Annexon, Inc. (the “Company”) announced certain financial results for the fourth quarter and the year ended December 31, 2023.”

Paysign, Inc. reported the fiscal year ended December 31, 2023 results: revenue $47.3 million, net income $6.5 million, EPS $0.12.

“PRESS RELEASE Exhibit 99.1 Earnings Release Paysign, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results For the Full Year · Full-year 2023 total revenues of $47.3 million, up 24% from full-year 2022 · Full-year 2023 net income of $6.5 million, or diluted earnings per share of $0.12, versus net income of $1.0 million, or diluted earnings per share”

COGNITION THERAPEUTICS INC reported the year ended December 31, 2023 results: net income $25.8 million, EPS $(0.86) per basic and diluted share.

“The Company reported a net loss of $25.8 million, or $(0.86) per basic and diluted share for the year ended December 31, 2023”

GameStop Corp. reported the fourth quarter and fiscal year ended February 3, 2024 results: revenue $1.794 billion for the fourth quarter, net income Net income was $63.1 million for the fourth quarter.

“and non-GAAP results, are below. The Company’s Form 10-K and supplemental information can be found at https://investor.gamestop.com . FOURTH QUARTER OVERVIEW • Net sales were $1.794 billion for the fourth quarter, compared to $2.226 billion in the prior year's fourth quarter. • Selling, general and administrative (“SG&A”) expenses were $359.2 million, or 20.0% of”

bluebird bio, Inc. reported the twelve months ended December 31, 2023 results: revenue $29.5 million.

“Total revenue, net was $29.5 million for the twelve months ended December 31, 2023, compared to $3.6 million for the twelve months ended December 31, 2022.”

bluebird bio, Inc. reported the three months ended December 31, 2023 results: revenue $7.8 million.

“Total revenue, net was $7.8 million for the three months ended December 31, 2023, compared to $0.1 million for the three months ended December 31, 2022.”

bluebird bio, Inc. reported financial results for the year ended December 31, 2023.

“On March 26, 2024, bluebird bio, Inc. (the “Company”) announced certain financial results for the three months and year ended December 31, 2023.”

TD SYNNEX CORP reported fiscal first quarter ended February 29, 2024 results: revenue $14.0 billion, net income $172 million, EPS $1.93.

“herewith as Exhibit 99.1. --- EX-99.1 (EX-99.1) --- TD SYNNEX Reports Fiscal 2024 First Quarter Results; Announces New $2B Share Repurchase Authorization • Revenue of $14.0 billion, within our outlook of $14.0 - $14.7 billion. • Non-GAAP gross billings (1) of $19.3 billion, within our outlook of $19.0 - $20.0 billion. • Gross margin and non-GAAP gross”

ACTELIS NETWORKS INC reported the fiscal full year 2023 ended December 31, 2023 results: revenue $5.6 million, net income $6.3 million.

“Total revenue was $5.6 million for the full year 2023, compared to $8.8 million in the prior year.”

GYRE THERAPEUTICS, INC. reported year ended December 31, 2023 results: revenue $112.1 million.

“inflammation modulators. ETUARY became commercially available in the PRC in 2011 and has been included in the National Reimbursement Drug List since 2017. • Generated sales of $112.1 million in 2023. For the year ended December 31, 2023, Gyre Pharmaceuticals generated $112.1 million in sales of ETUARY, representing an increase of 13% from the previous year. As of”

Marker Therapeutics, Inc. reported financial results for the fiscal year ended December 31, 2023.

“On March 25, 2024, Marker Therapeutics, Inc. (the “ Company ”) reported financial results for the fiscal year ended December 31, 2023 and other recent corporate updates.”